# Fulvestrant

## Faslodex inj 250mg/5mL

##### 臨採

| TAH Drug Code      | [IFAS](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IFAS)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|:-------------------|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Breast cancer, metastatic, breast cancer, advanced or metastatic (second-line endocrine-based combination therapy)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Dosing             | 500 mg administered intramuscularly into the buttocks (gluteal area) slowly (1 -2 minutes per injection) as two 5 mL injections, one in each buttock, on Days 1, 15, 29, and once monthly thereafter.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Hepatic Impairment | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Renal Impairment   | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Contraindications  | a) hypersensitivity to fulvestrant or to any of its components b) suspected or known pregnancy Precautions A) hepatic impairment Serious Adverse Effects: a) Anemia b) Angioedema                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Adverse Effects    | >10%: Central nervous system: Fatigue (8% to 29%), headache (8% to 20%) Gastrointestinal: Nausea (10% to 28%), diarrhea (19%), constipation (5% to 16%), stomatitis (13%) Hematologic & oncologic: Anemia (13% to 40%; grade 3: 2%) Hepatic: Increased liver enzymes (>15%; grades 3/4: 1% to 2%) Infection: Infection (31%; including nasopharyngitis, upper respiratory infection, urinary tract infection, influenza, bronchitis, rhinitis, conjunctivitis, pneumonia, sinusitis, cystitis, oral herpes, respiratory tract infection) Local: Pain at injection site (12%; including neuralgia, peripheral neuropathy, sciatica) 1% to 10%: Dermatologic: Alopecia (6%), skin rash (6%), xeroderma (1%) Endocrine & metabolic: Hot flash (7%) Gastrointestinal: Decreased appetite (8%), anorexia (6%), vomiting (6%), dysgeusia (3%) Hematologic & oncologic: Decreased platelet count (10%), leukopenia (5%; grade 3: 1%; grade 4: 1%), neutropenia (4%; grade 3: 1%), febrile neutropenia (1%; grade 4: 1%) Neuromuscular & skeletal: Ostealgia (9%), arthralgia (8%), back pain (8%), limb pain (7%), musculoskeletal pain (6%), weakness (5% to 6%) Ophthalmic: Blurred vision (2%), dry eye syndrome (2%), increased lacrimation (1%) Respiratory: Cough (5%), dyspnea (4%), epistaxis (2%) |
| Pregnancy          | Contraindicated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Lactation          | Contraindicated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| More Info          | [UpToDate](https://www.uptodate.com/contents/fulvestrant-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |

